Respiratory Failure
Conditions
Brief summary
L-Carnitine supplementation has been shown to boost muscular performance in several studies. In hemodialysis patients with muscular weakness, fatigue, or cramps/aches, after L-carnitine treatment, about two-thirds of patients had at least some improvement in muscular symptoms . L-Carnitine was also found to improve the left ventricular ejection fraction (LVEF) in hemodialysis patients with cardiac morbidity who had significantly reduced LVEF in echocardiography before supplementation. Moreover, L-Carnitine has been shown to improve muscular function and exercise performance in athletes in several studies
Interventions
DRUGL Carnitine ( low dose)
will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
DRUGL-Carnitine ( high dose)
will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
Sponsors
Ain Shams University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age from 21 years old or greater * Both genders have respiratory failure either of the primary medical origin or in the post-surgical course. * Not in need of mechanical ventilation
Exclusion criteria
* Renal failure on regular dialysis * Hypothyroidism * Seizures * End-stage liver disease * Mechanical ventilation * History or discovered allergy to L-carnitine, pivampicillin, and other pivalate-conjugated antibiotics.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ultrasound diaphragmatic function | at days 7 | Diaphragmatic excursion by ultrasound |
Countries
Egypt
Outcome results
None listed